Abstract:Background:Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) both have consistent expression of CD30, a cytokine receptor that is expressed by activated T and B cells but is largely absent from normal tissue.Methods:A literature search was conducted via PubMed, Google Scholar, and UpToDate to identify relevant peer-reviewed original research or review articles on HL, sALCL, and CD30 targeted therapies.Results:These lymphomas are both more common among males, young adults and the elderly. Although many patients with HL and sALCL can achieve long-term remission after standard first-line therapy, up to a third of these patients are refractory to or relapse after initial therapy. Among these relapsed/refractory patients, many experience disease progression and/or death despite subsequent treatment, and treatment-related adverse events and mortality are not uncommon. To address the need for safer and more effective therapies for these relapsed/refractory patients, researchers have developed therapies that specifically target CD30-expressing cells. Brentuximab vedotin, an antibody-drug conjugate that selectively delivers a toxic microtubule-disrupting agent to malignant cells with CD30 expression, is the first such therapy to be approved in the US and Europe. In clinical trials, brentuximab vedotin has demonstrated efficacy and safety in patients with HL after failure of autologous stem cell transplantation (ASCT), or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and in patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.Conclusion:HL and sALCL are both CD30+ lymphomas, and therapies like brentuximab vedotin that target cells expressing CD30 hold promise for the treatment of these diseases.

Acitretin Combined with NB‐UVB in the Treatment of Cutaneous CD30‐positive Anaplastic Large Cell Lymphoma

Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders: a clinicopathological analysis of 5 cases

Primary Cutaneous CD30-positive Anaplastic Large Cell Lymphoma Analysis.

Primary Cutaneous ALK+CD30+ Anaplastic Large Cell Lymphoma: a Case Report

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma

A case of CD30+ cutaneous T-cell lymphoma accompanied with bullous pemphigoid

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Observation of the therapeutic efficacy of acitretin combined with narrow-band ultraviolet

Oral Acitretin Combined with Surgical Excision for the Treatment of Multiple Bowen's Disease and Squamous Cell Carcinoma: a Case Report

Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod

The Epidemiology And Targeted Therapies For Relapsed And Refractory Cd30+Lymphomas

Gene rearrangement in T-cell receptor γ and immunoglobulin heavy chain for primary cutaneous anaplastic large cell lymphoma

5-Aminolevulinic Acid Photodynamic Therapy Enhance the Effect of Acitretin on Squamous Cell Carcinoma Cells: an in Vitro Study

Primary Cutaneous CD30~+ Anaplastic Large Cell Lymphoma: a Case Report

Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma

Homozygous Loss of CDKN2 in Primary Cutaneous CD8(+) Lymphoma NOS

Case Report: Successful Treatment of Cutaneous Squamous Cell Carcinoma in Three Patients With a Combination of Acitretin and Clarithromycin

Primary cutaneous anaplastic large-cell lymphoma with 6p25.3 rearrangement exhibits a biphasic histopathologic pattern: Two case reports and literature review